Last reviewed · How we verify
Xofigo
At a glance
| Generic name | Xofigo |
|---|---|
| Also known as | Radium -223, radium-223 |
| Sponsor | Bayer |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Malignant tumor of prostate
Common side effects
- Anemia
- Nausea
- Lymphocytopenia
- Diarrhea
- Leukopenia
- Vomiting
- Thrombocytopenia
- Peripheral edema
- Neutropenia
- Pancytopenia
- Renal failure and impairment
Serious adverse events
- Lymphocytopenia (Grade 3-4)
- Anemia (Grade 3-4)
- Thrombocytopenia (Grade 3-4)
- Leukopenia (Grade 3-4)
- Neutropenia (Grade 3-4)
- Nausea (Grade 3-4)
- Diarrhea (Grade 3-4)
- Vomiting (Grade 3-4)
- Peripheral edema (Grade 3-4)
- Renal failure and impairment (Grade 3-4)
Key clinical trials
- Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (PHASE2)
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy (PHASE1, PHASE2)
- Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (PHASE2)
- Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (PHASE1)
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) (PHASE4)
- Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer (PHASE2)
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases (PHASE3)
- Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xofigo CI brief — competitive landscape report
- Xofigo updates RSS · CI watch RSS
- Bayer portfolio CI